Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metab… Read more
Market Cap & Net Worth: Innovent Biologics Inc (IVBXF)
Innovent Biologics Inc (PINK:IVBXF) has a market capitalization of $10.58 Billion ($10.58 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #1743 globally and #1283 in its home market, demonstrating a 15.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innovent Biologics Inc's stock price $6.15 by its total outstanding shares 1720801070 (1.72 Billion).
Innovent Biologics Inc Market Cap History: 2019 to 2025
Innovent Biologics Inc's market capitalization history from 2019 to 2025. Data shows growth from $5.85 Billion to $10.58 Billion (12.70% CAGR).
Innovent Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innovent Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.89x
Innovent Biologics Inc's market cap is 0.89 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $5.85 Billion | $1.05 Billion | -$1.72 Billion | 5.59x | N/A |
| 2020 | $17.64 Billion | $3.84 Billion | -$998.42 Million | 4.59x | N/A |
| 2021 | $10.58 Billion | $4.27 Billion | -$2.73 Billion | 2.48x | N/A |
| 2022 | $7.37 Billion | $4.56 Billion | -$2.18 Billion | 1.62x | N/A |
| 2023 | $8.47 Billion | $6.21 Billion | -$1.03 Billion | 1.36x | N/A |
| 2024 | $8.35 Billion | $9.42 Billion | -$94.63 Million | 0.89x | N/A |
Competitor Companies of IVBXF by Market Capitalization
Companies near Innovent Biologics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Innovent Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Innovent Biologics Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, Innovent Biologics Inc's market cap moved from $5.85 Billion to $ 10.58 Billion, with a yearly change of 12.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.58 Billion | +26.80% |
| 2024 | $8.35 Billion | -1.42% |
| 2023 | $8.47 Billion | +14.82% |
| 2022 | $7.37 Billion | -30.33% |
| 2021 | $10.58 Billion | -40.00% |
| 2020 | $17.64 Billion | +201.47% |
| 2019 | $5.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Innovent Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.58 Billion USD |
| MoneyControl | $10.58 Billion USD |
| MarketWatch | $10.58 Billion USD |
| marketcap.company | $10.58 Billion USD |
| Reuters | $10.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.